
    
      This is a single-center, single-arm, open-label study. This study is planned to enroll about
      9 subjects with relapsed or refractory acute myelogenous leukemia and 9 matched donors for
      leukapheresis and CAR-T cells manufacture. Donor-derived CAR-T cells were then infused
      intravenously into subjects, in a dose-escalating 3+3 design.
    
  